Alerta

METHODS OF TREATING MULTIPLE MYELOMA WITH BCMA INHIBITORS IN COMBINATION WITH CD38 INHIBITORS

Absstract of: WO2026059919A1

The present disclosure provides methods for treating multiple myeloma. In certain embodiments, the present methods comprise administering to a subject in need thereof a BCMA inhibitor (e.g., a bispecific antibody or antigen-binding fragment thereof that bind to BCMA and CD3) in combination with a CD38 inhibitor (e.g., an anti-CD38 antibody). In certain embodiments, the subject has been previously treated with one or more anti-cancer therapies.

METHODS OF TREATING MULTIPLE MYELOMA WITH BCMA INHIBITORS IN COMBINATION WITH PROTEASOME INHIBITORS

Absstract of: WO2026059917A1

The present disclosure provides methods for treating multiple myeloma. In certain embodiments, the present methods comprise administering to a subject in need thereof a BCMA inhibitor in combination with a proteasome inhibitor. In certain embodiments, the subject has been previously treated with one or more anti-cancer therapies. In certain embodiments, the proteasome inhibitor is carfilzomib.

BIS-CHLOROETHYLAMINO DERIVATIVES FOR TREATING LEUKEMIA

Absstract of: WO2026057823A1

The invention provides compounds of formula (I), that are peptidase enhanced cytotoxics for use for use in the treatment of and/or prophylaxis of BCL2 inhibitor resistant or refractory acute myeloid leukaemia (AML). (Formula)

METHODS FOR TREATING CANCER USING SUBCUTANEOUS DOSING OF MOSUNETUZUMAB IN COMBINATION WITH POLATUZUMAB VEDOTIN

Absstract of: US20260078198A1

The present invention relates to the treatment of subjects having a CD20-positive cell proliferative disorder (e.g., B cell proliferative disorders, such as a non-Hodgkin's lymphoma (NHL); e.g., an aggressive NHL or a relapsed and/or refractory NHL). More specifically, the invention pertains to the treatment of subjects having a B cell proliferative disorder by administering a combination of mosunetuzumab and polatuzumab vedotin.

METHODS OF TREATING MULTIPLE MYELOMA WITH BCMA INHIBITORS IN COMBINATION WITH AN IMMUNOMODULATOR

Absstract of: WO2026059923A1

The present disclosure provides methods for treating multiple myeloma. In certain embodiments, the present methods comprise administering to a subject in need thereof a BCMA inhibitor (e.g., a bispecific antibody or antigen-binding fragment thereof that binds to BCMA and CD3) in combination with an immunomodulator. In certain embodiments, the immunomodulator is a structural or functional analogue of thalidomide (e.g., lenalidomide or pomalidomide). In certain embodiments, the subject has been previously treated with one or more anti-cancer therapies.

METHODS OF TREATING MULTIPLE MYELOMA WITH BCMA INHIBITORS IN COMBINATION WITH PD1/PD-L1 INHIBITORS

Absstract of: WO2026059920A1

The present disclosure provides methods for treating multiple myeloma. In certain embodiments, the present methods comprise administering to a subject in need thereof a BCMA inhibitor (e.g., a bispecific antibody or antigen-binding fragment thereof that binds to BCMA and CD3) in combination with a PD1 inhibitor or PD-L1 inhibitor (e.g., an anti-PD1 antibody or an anti-PD-L1 antibody). In certain embodiments, the subject has been previously treated with one or more anti-cancer therapies.

B CELL LYMPHOMA MUTATIONS, COMPOSITIONS, AND USES TO ENHANCE ENGINEERED T CELL THERAPIES

Absstract of: WO2026060398A2

The present disclosure relates generally to mutations in B cell lymphoma, and methods of use of the mutations in T cell therapy.

T CELL LYMPHOMA MUTATIONS, COMPOSITIONS, AND USES TO ENHANCE ENGINEERED T CELL THERAPIES

Absstract of: WO2026060399A2

The present disclosure relates generally to mutations in T cell lymphoma, and methods of use of the mutations in T cell therapy.

ANTI-HUMAN TIM3 ANTIBODIES FOR IN VITRO DIAGNOSTICS

Absstract of: WO2026059950A1

The disclosure provides binding agents (e.g., antibodies) against a human Hepatitis A virus cellular receptor 2 protein (TIM3), as well as kits and methods for using the same (e.g., immunoassays) as part of a companion diagnostic and for other applications. In some aspects, the binding agents described herein may be used in assays for detecting Non-Small Cell Lung Cancer (NSCLC) and/or other types of lung cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Hepatocellular Carcinoma (HCC) or other types of liver cancer, Renal cell carcinoma, malignant melanoma, gastro-intestinal cancer, colorectal cancer, urothelial carcinoma and other types of bladder cancer, mamma carcinoma and/or other types of breast cancer, ovarian cancer, cervical cancer, prostate cancer, pancreatic cancer, lymphoma/leukemia, malignant mesothelioma, or a cancer in another organ or cell type.

USE OF MICRO PEPTIDE MIAC

Absstract of: EP4711382A1

Use of a micropeptide MIAC, which belongs to the technical field of biomedicine. The present disclosure specifically relates to use of the micropeptide MIAC in preparation of a reagent or a medicament for detecting, preventing or treating tumors. The tumors comprise one or more of solid tumors and hematologic malignancies, such as pancreatic cancer, hepatocellular carcinoma, colorectal cancer, ovarian cancer, cervical cancer, bladder cancer, melanoma, glioblastoma, neuroblastoma, glioma, osteosarcoma, lymphoma, hematologic malignancies, myeloma, cholangiocarcinoma and prostate cancer. The micropeptide MIAC has the effects of inhibiting growth, proliferation and/or migration of various tumor cells, has a wide treatment spectrum, and is suitable for diagnosing, preventing or treating various tumors, specifically malignant tumors.

METHOD FOR THE MANUFACTURE OF INDIVIDUALIZED CRISPR/CAS COMPLEXES AND INDIVIDUALIZED CRISPR/CAS COMPLEXES

Absstract of: EP4711456A1

The present invention relates to a method for the manufacture of individualized CRISPR/Cas complexes comprising the steps a) identifying in a tumor specimen of a human cancer patient a mutation at position 38.141.150 on chromosome 3, and b) preparing for the mutation identified in a) an individualized CRISPR/Cas complex, wherein the individualized CRISPR/Cas complex comprises a guide RNA and a Cas endonuclease, wherein the CRISPR/Cas complex targets the mutation; a method, preferably an in-vitro method, for inducing cell death or impairment of cell proliferation in cancerous or pre-cancerous cells of B-cell-lymphocytes; a composition related thereto and individualized CRISPR/Cas complexes preferably for use in the treatment of B-cell-lymphoma or for inducing cell death or impairment of cell proliferation in cancerous or pre-cancerous B-cell-lymphocytes.

ENDOTHELIAL CELLS FOR MITIGATION OF CHEMOTHERAPY-INDUCED TOXICITY

Absstract of: EP4711444A2

The present invention provides compositions and methods for the mitigation of side effects of chemotherapy, for example in human subjects with hematologic malignancies (such as lymphoma, leukemia and myelodysplastic syndrome) as well as subjects with other malignancies or other conditions that may be treated with chemotherapy, such as high dose therapy (HDT) or a combination of high dose HDT and a hematopoietic stem cell transplant. The methods comprise administration of endothelial cells, such as engineered human umbilical vein endothelial cells engineered to express the adenoviral E4ORF1 protein (E4ORF1+ HUVECs), to human subjects. The side effects mitigated by the compositions and methods of the invention include, but are not limited to, oral / gastrointestinal side effects and febrile neutropenia.

LIPID COMPLEX

Absstract of: EP4711463A1

Problem A composition and a method that can be used to induce an immune response to HTLV-1 are required.Solution A lipid complex comprising at least one nucleic acid selected from: a nucleic acid comprising a polynucleotide that encodes an immunogenic fragment of human T-cell leukemia virus 1 (HTLV-1) antigenic Gag protein; a nucleic acid comprising a polynucleotide that encodes an immunogenic fragment of HTLV-1 antigenic Tax protein; and a nucleic acid comprising a polynucleotide that encodes an immunogenic fragment of HTLV-1 antigenic HBZ protein; wherein the at least one nucleic acid is encapsulated in a lipid.

PHARMACEUTICAL COMPOSITION

Absstract of: EP4710937A1

Problem The purpose is to provide a novel pharmaceutical composition that can be used to induce an immune response to HTLV-1. Solution The pharmaceutical composition of the present disclosure comprises: human T-cell leukemia virus 1 (HTLV-1) antigenic Gag protein p15 (Gag p15) or an immunogenic fragment thereof, Gag protein p19 (Gag p19) or an immunogenic fragment thereof, and/or Gag protein p24 (Gag p24) or an immunogenic fragment thereof; and a pharmaceutically acceptable carrier

PRODUCTION OF VIRAL STOCKS

Absstract of: WO2026055296A2

Methods of producing Minute Mouse Virus (MMV) stock are described herein. Methods of producing xenotropic murine leukemia virus (xMuLV) stock are described herein.

COMPOUNDS FOR THE TARGETED DEGRADATION OF B-CELL LYMPHOMA 6 (BCL6)

Absstract of: WO2026055403A1

Provided are compounds of the Formula PTM-L-CLM, or a pharmaceutically acceptable salt thereof, wherein the PTM is (PTM-I) These compounds are useful for the degradation of BCL6 and in the treatment cancer.

TREATMENT SELECTION FOR PERSONALIZED LYMPHOMA TREATMENT

Absstract of: WO2026055154A1

The present disclosure provides methods and kits for obtaining sequence information of one or more genes from a subject diagnosed with a disease or disorder. Based on the sequence information, the present disclosure further provides methods of predicting a treatment outcome of the subject.

TYR PEPTIDE COMPOSITIONS AND METHODS FOR USE

Absstract of: US20260070946A1

The present disclosure, relates, in general to analogs of proline-rich polypeptide 1 (PRP-1) designated tyrosine peptides (TYR peptide) that are useful to treat cancer, such as sarcomas, carcinomas and leukemias or liquid cancers.

BISPHOSPHONATE LIPIDS, LIPID NANOPARTICLE COMPOSITIONS COMPRISING THE SAME, MINERAL TISSUE-ADSORBED COMPOSITIONS THEREOF, AND METHODS OF USE THEREOF

Absstract of: US20260070935A1

Described herein, in part, are bisphosphonate lipid compounds, lipid nanoparticles (LNPs) thereof, and methods of use thereof. In various embodiments, the LNP selectively targets a cell of interest (e.g., a bone cell and/or bone marrow cell, such as a stem cell, stroma cell, osteoblast, osteocyte, osteoclast, bone lining cell, local mesenchymal cell, progenitor cell, mononuclear blood-borne precursor cell, B cell, endothelial cell, granulocytes, T cell, monocytic lineage, B cell lineage, monocytes, cancer cell, tumor cell, tumor cell that metastasize to bone, blood cancer cell, and multiple myeloma cell, inter alia). In other aspects, the present disclosure relates to methods for in vivo delivery of therapeutic agents to prevent or treat diseases, disorders, or conditions using the LNP compositions of the disclosure.

ANTI-GPRC5D ANTIBODIES AND COMPOSITIONS

Absstract of: AU2024317966A1

The present disclosure provides antigen-binding proteins specifically binding GPRC5D, as well as respective antibodies in enhanced ADCC formats, and methods of using them to treat cancers such as multiple myeloma.

METHODS OF TREATING MULTIPLE MYELOMA WITH BCMA INHIBITORS IN COMBINATION WITH CD38 INHIBITORS

Absstract of: US20260070998A1

The present disclosure provides methods for treating multiple myeloma. In certain embodiments, the present methods comprise administering to a subject in need thereof a BCMA inhibitor (e.g., a bispecific antibody or antigen-binding fragment thereof that bind to BCMA and CD3) in combination with a CD38 inhibitor (e.g., an anti-CD38 antibody). In certain embodiments, the subject has been previously treated with one or more anti-cancer therapies.

REVERSE TRANSCRIPTASE MUTANTS WITH INCREASED ACTIVITY AND THERMOSTABILITY

Absstract of: US20260071196A1

The disclosure provides Moloney murine leukemia virus (MMLV) reverse transcriptase (RTase) mutants. The disclosure as provides suitable amino acid positions in MMLV RTase for mutagenesis and methods and kits for using MMLV RTase mutants to synthesize cDNA from RNA templates.

METHODS FOR TREATING AND SELECTING CANCER PATIENTS

Absstract of: WO2026055333A1

The invention provides methods for treating and selecting cancer patients for therapy using a compound that modulates mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) activity, such as inhibiting MALT1 scaffolding activity.

GUIDING AND AUGMENTING NK CELL-BASED THERAPIES IN HIGH HLA-E EXPRESSING HUMAN CANCERS SUCH AS LEUKAEMIA

Absstract of: WO2026054717A1

Disclosed herein are methods of enhancing the abundance of NKG2C+ adaptive NK cells in a population of NK cells and the use of NK cells expressing NKG2C derived from such methods for treatment of cancers, including leukemia such as chronic myeloid leukemia with enhanced expression of HLA-E molecule. In one embodiment, the method is a biphasic method comprising a selection phase and an expansion phase. In one embodiment, the selection phase comprises use of a first culture comprising IL-2 and feeder cells expressing HLA-E. In one embodiment, the expansion phase comprises use of a second culture comprising IL-2, IL-15 and feeder cells expressing HLA-E, IL-21 and 4-1 BBL. Also disclosed are methods of stratifying chronic myeloid leukemia patients into responders or non-responders to tyrosine kinase inhibitor to allow a suitable treatment for each group with tyrosine kinase inhibitor or NK cells expressing NKG2C derived from the described methods. In one embodiment, the stratification method comprises determining a percentage of NKG2A+ cells in the patients' NK cell population.

COMBINATION CBL-BI AND ANTIHISTAMINE FOR CANCER THERAPY

Nº publicación: WO2026055492A1 12/03/2026

Applicant:

HOTSPOT THERAPEUTICS INC [US]
HOTSPOT THERAPEUTICS, INC

Absstract of: WO2026055492A1

Disclosed herein are methods of administering a Casitas B-lineage lymphoma proto-oncogene B inhibitor (CBL-Bi) for treating a cancer in a subject. Additionally disclosed herein are methods of administering a pre-treatment in combination with the CBL-Bi for treating a cancer in a subject.